Correlation Between Unicycive Therapeutics and BioAffinity Technologies

Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and BioAffinity Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and BioAffinity Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Unicycive Therapeutics and bioAffinity Technologies Warrant, you can compare the effects of market volatilities on Unicycive Therapeutics and BioAffinity Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of BioAffinity Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and BioAffinity Technologies.

Diversification Opportunities for Unicycive Therapeutics and BioAffinity Technologies

-0.61

Correlation Coefficient

Unicycive Therapeutics  BioAffinity Technologies

Excellent diversification

The 3 months correlation between Unicycive and BioAffinity is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and bioAffinity Technologies Warra in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioAffinity Technologies and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with BioAffinity Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioAffinity Technologies has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and BioAffinity Technologies go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and BioAffinity Technologies

Given the investment horizon of 90 days Unicycive Therapeutics is expected to generate 0.33 times more return on investment than BioAffinity Technologies. However, Unicycive Therapeutics is 3.01 times less risky than BioAffinity Technologies. It trades about 0.23 of its potential returns per unit of risk. bioAffinity Technologies Warrant is currently generating about 0.0 per unit of risk. If you would invest  35.00  in Unicycive Therapeutics on September 5, 2024 and sell it today you would earn a total of  36.00  from holding Unicycive Therapeutics or generate 102.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	93.75%
Values	Daily Returns

Unicycive Therapeutics  vs.  bioAffinity Technologies Warra

Unicycive Therapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

BioAffinity Technologies

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days bioAffinity Technologies Warrant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable technical and fundamental indicators, BioAffinity Technologies is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Pair Trading with Unicycive Therapeutics and BioAffinity Technologies

The main advantage of trading using opposite Unicycive Therapeutics and BioAffinity Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, BioAffinity Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioAffinity Technologies will offset losses from the drop in BioAffinity Technologies' long position.

The idea behind Unicycive Therapeutics and bioAffinity Technologies Warrant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.